Efficacy of Abemaciclib in the Management of Refractory Metastatic Extramammary Paget’s Disease
Open Access
- 1 August 2022
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e27534
Abstract
Published systemic therapy options for metastatic extramammary Paget's disease have largely been anecdotal due to the rarity of this disease, which has precluded the ability to conduct clinical trials. We describe the favorable response of a 72-year-old man with extramammary Paget's disease, whose disease has been controlled with the CDK4/6 inhibitor, abemaciclib. The rationale behind the selection of this therapy is discussed.Keywords
This publication has 6 references indexed in Scilit:
- Cyclin‐dependent kinase 4/6 inhibitors suppress tumor growth in extramammary Paget’s diseaseCancer Science, 2021
- Modified peripheral and central Mohs micrographic surgery for improved margin control in extramammary Paget diseaseJAAD Case Reports, 2021
- Overexpression of cyclin‐dependent kinase 4 protein in extramammary Paget's diseaseThe Journal of Dermatology, 2019
- Mammary and Extramammary Paget’s Disease Presented Different Expression Pattern of Steroid Hormone ReceptorsBioMed Research International, 2017
- Management of Penoscrotal Extramammary Paget Disease: Case Series and Review of the LiteratureCurrent Oncology, 2013
- Estrogen-Receptor-Alpha-Positive Extramammary Paget’s Disease Treated with Hormonal TherapyDermatology, 2006